3rd Quarter - Report

MICHAEL N. MCCARTY LAW OFFICE PLLC for AMERICAN MEDICAL TECHNOLOGISTS

Firm
Client
Income
$10,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Legislation affecting payment for clinical laboratory diagnostic tests, including but not limited to COVID-19 tests; Promote legislative amendments to section 216 of the Protecting Access to Medicare Act of 2014 (PAMA) to implement Medicare Payment Advisory Commission (MedPAC) recommendations to Congress on prospective improvements to methodologies for market pricing of the Medicare Clinical Laboratory Fee Schedule.

LobbyistCovered position, as disclosed
MICHAEL N MCCARTY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128; support initiatives to improve clinical laboratory testing supply chains.

LobbyistCovered position, as disclosed
MICHAEL N MCCARTY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2209 (117th), S. 1666 (117th), H.R. 4128 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.